Isofol Medical AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
For the six months, sales was SEK 0.721 million compared to SEK 8.03 million a year ago. Revenue was SEK 0.745 million compared to SEK 8.03 million a year ago. Net loss was SEK 21.9 million compared to SEK 101.91 million a year ago. Basic loss per share from continuing operations was SEK 0.14 compared to SEK 0.63 a year ago. Diluted loss per share from continuing operations was SEK 0.14 compared to SEK 0.63 a year ago.